In yesterday’s Wall Street session, BioSig Technologies Inc. (NASDAQ:BSGM) shares traded at $1.19, down -14.39% from the previous session.
3 analysts cover BioSig Technologies Inc. (NASDAQ:BSGM), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $2.00, we find $5.50. Given the previous closing price of $1.39, this indicates a potential upside of 295.68 percent. BSGM stock price is now -7.38% away from the 50-day moving average and 27.51% away from the 200-day moving average. The market capitalization of the company currently stands at $98.00M.
The stock has received a hold rating from 0 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $4.50 as their price target over the next twelve months.
With the price target of $9, ROTH Capital recently initiated with Buy rating for BioSig Technologies Inc. (NASDAQ: BSGM).
In other news, LONDONER KENNETH L, Chief Executive Officer bought 15,600 shares of the company’s stock on Jun 13. The stock was bought for $19,358 at an average price of $1.24. Upon completion of the transaction, the Chief Executive Officer now directly owns 2,507,020 shares in the company, valued at $2.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 12, Chief Executive Officer LONDONER KENNETH L bought 6,000 shares of the business’s stock. A total of $7,040 was incurred on buying the stock at an average price of $1.17. This leaves the insider owning 2,491,420 shares of the company worth $2.96 million. A total of 7.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BSGM stock. A new stake in BioSig Technologies Inc. shares was purchased by PFG INVESTMENTS, LLC during the first quarter worth $78,000. AE WEALTH MANAGEMENT LLC invested $24,000 in shares of BSGM during the first quarter. In the first quarter, TWO SIGMA SECURITIES, LLC acquired a new stake in BioSig Technologies Inc. valued at approximately $16,000. JOHNSON FINANCIAL GROUP, INC. acquired a new stake in BSGM for approximately $6,000. RONALD BLUE TRUST, INC. purchased a new stake in BSGM valued at around $4,000 in the second quarter. In total, there are 54 active investors with 9.50% ownership of the company’s stock.
On Friday morning BioSig Technologies Inc. (NASDAQ: BSGM) stock kicked off with the opening price of $1.3000. During the past 12 months, BioSig Technologies Inc. has had a low of $0.25 and a high of $1.65. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 0.80, and a quick ratio of 0.60. The fifty day moving average price for BSGM is $1.2818 and a two-hundred day moving average price translates $0.9359 for the stock.
The latest earnings results from BioSig Technologies Inc. (NASDAQ: BSGM) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.1 by -0.02. This compares to -$0.22 EPS in the same period last year. The company reported revenue of $5000.0 for the quarter, compared to $8000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -37.5 percent. For the current quarter, analysts expect BSGM to generate $100k in revenue.
BioSig Technologies Inc.(BSGM) Company Profile
BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias. The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
